Novo Holdings is a holding and investment company responsible for managing the assets of the Novo Nordisk Foundation, operating as a life sciences investor with €142bn in total assets.
The round was co-led by Plural, Playground Global, and Novo Holdings.
"We’re actively creating quantum advantage at Phasecraft. Our algorithms are delivering meaningful results now, whether it’s simulating the physics of complex materials or optimizing the structure of a large energy network, whilst our partnerships with the world’s top quantum hardware providers increase the impact our algorithms will have for commercial applications. We’re delighted to have the backing of our visionary investors such as Plural, Playground Global, and Novo Holdings, to support us on the mission to bring quantum advantage to the world faster."
Novo Holdings, Glenview Capital and b2venture led the Series E round, which will fund commercial expansion in the US.
"Our commitment to delivering innovative solutions for acute care has never been stronger. This financing round provides the resources to solidify Quanta as the best-in-class solution across the care continuum, to significantly expand our commercial operations, while continuing to introduce enhancements that will strengthen our long-term competitive position."
The financing round was led by Glenview Capital and co-led by Novo Holdings.
"Everybody knows that dialysis care must improve. For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care. Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this market."
The financing was led by SoftBank Vision Fund 2 with participation from Novo Holdings and Blackrock to expand the proprietary drug pipeline.
"We believe Exscientia’s innovative use of AI to discover and design better quality drugs with greater efficiency has the potential to create important medicines faster than ever before. With the convergence of technology and biology, drug discovery is rapidly evolving in ways that will reshape the industry. The Exscientia team have been leaders in AI-based drug discovery since the field’s inception and we believe they will continue shaping its future."
— Eric Chen, Managing Partner of SoftBank Investment Advisers
